Evanson Asset Management LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 20.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,079 shares of the medical research company’s stock after selling 280 shares during the quarter. Evanson Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $241,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the stock. IMS Capital Management bought a new position in Thermo Fisher Scientific during the third quarter valued at $53,000. Cornerstone Advisors Inc. increased its position in Thermo Fisher Scientific by 33.3% during the third quarter. Cornerstone Advisors Inc. now owns 332 shares of the medical research company’s stock valued at $81,000 after acquiring an additional 83 shares during the last quarter. Legacy Financial Advisors Inc. increased its position in Thermo Fisher Scientific by 77.2% during the fourth quarter. Legacy Financial Advisors Inc. now owns 450 shares of the medical research company’s stock valued at $101,000 after acquiring an additional 196 shares during the last quarter. Banco de Sabadell S.A bought a new position in shares of Thermo Fisher Scientific in the third quarter worth about $122,000. Finally, Prime Capital Investment Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 396.0% in the third quarter. Prime Capital Investment Advisors LLC now owns 620 shares of the medical research company’s stock worth $151,000 after purchasing an additional 495 shares during the last quarter. 86.88% of the stock is currently owned by institutional investors.
TMO has been the topic of a number of research analyst reports. Citigroup upped their price target on shares of Thermo Fisher Scientific from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Wednesday, October 10th. UBS Group initiated coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 9th. They issued a “buy” rating and a $295.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $274.00 price target on the stock in a report on Monday, October 1st. Three analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average price target of $271.10.
Shares of Thermo Fisher Scientific stock opened at $238.17 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.27 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a 1 year low of $194.51 and a 1 year high of $253.91. The stock has a market cap of $94.79 billion, a price-to-earnings ratio of 25.10, a price-to-earnings-growth ratio of 1.54 and a beta of 1.08.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 24th. The medical research company reported $2.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.07. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The company had revenue of $5.92 billion for the quarter, compared to analysts’ expectations of $5.70 billion. During the same period in the prior year, the business earned $2.31 EPS. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 11.05 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, January 15th. Shareholders of record on Monday, December 17th were issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 0.29%. The ex-dividend date was Friday, December 14th. Thermo Fisher Scientific’s payout ratio is 7.17%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: Relative Strength Index
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.